Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EXAS stock price vs IPI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IPI's multiple
Needs IPI P/S.
Implied fair value · at EXAS's multiple
Needs EXAS P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXAS FY 2025 (ended Dec 31, 2025) · IPI FY 2025 (ended Dec 31, 2025).
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EXACT SCIENCES CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
INTREPID POTASH, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.19x
0.16x
Net debt / EBITDA
Leverage against operating earnings
35.68x
-0.10x
Cash and equivalents
Liquid reserves on the balance sheet
$964.71M
$83.54M
Total debt
Interest-bearing obligations outstanding
$2.85B
$78.77M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Guardant Health, Inc.
EXAS vs GH
Natera, Inc.
EXAS vs NTRA
NEOGENOMICS INC
EXAS vs NEO
OPKO HEALTH, INC.
EXAS vs OPK
LABCORP HOLDINGS INC.
EXAS vs LH
QUEST DIAGNOSTICS INC
EXAS vs DGX
MOSAIC CO
EXAS vs MOS
Nutrien Ltd.
EXAS vs NTR
COMPASS MINERALS INTERNATIONAL INC
EXAS vs CMP
CVR PARTNERS, LP
EXAS vs UAN
Archer-Daniels-Midland Co
EXAS vs ADM
CF Industries Holdings, Inc.
EXAS vs CF
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
